Related references
Note: Only part of the references are listed.Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation
G. Fountzilas et al.
ANNALS OF ONCOLOGY (2012)
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial
Helen Gogas et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial
P. Skarlos et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
K. Albain et al.
LANCET (2012)
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
E. Razis et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Docetaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy for Patients with Primary Breast Cancer
Hiroji Iwata et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2011)
Randomized, Phase III Trial of Sequential Epirubicin and Docetaxel Versus Epirubicin Alone in Postmenopausal Patients With Node-Positive Breast Cancer
R. Charles Coombes et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2-Normal, Node-Positive Breast Cancer: BCIRG-005 Trial
Wolfgang Eiermann et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Alteration of Topoisomerase II-Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based Chemotherapy
Michael F. Press et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Adjuvant Chemotherapy, with or without Taxanes, in Early or Operable Breast Cancer: A Meta-Analysis of 19 Randomized Trials with 30698 Patients
Ying-Yi Qin et al.
PLOS ONE (2011)
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study
Harri Sihto et al.
BREAST CANCER RESEARCH (2011)
Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial
Jocelyne Jacquemier et al.
BREAST CANCER RESEARCH (2011)
Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer
Miguel Martin et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Breast Cancer Classification According to Immunohistochemistry Markers: Subtypes and Association With Clinicopathologic Variables in a Peruvian Hospital Database
Carlos S. Vallejos et al.
CLINICAL BREAST CANCER (2010)
Breast Cancer Subtypes and the Risk of Local and Regional Relapse
K. David Voduc et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Metastatic Behavior of Breast Cancer Subtypes
Hagen Kennecke et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer
Philippe L. Bedard et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies
Fiona M. Blows et al.
PLOS MEDICINE (2010)
Survival among women with triple receptor-negative breast cancer and brain metastases
S. Dawood et al.
ANNALS OF ONCOLOGY (2009)
Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer
Marjorie Zauderer et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Prediction of Local Recurrence, Distant Metastases, and Death After Breast-Conserving Therapy in Early-Stage Invasive Breast Cancer Using a Five-Biomarker Panel
Ewan K. A. Millar et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Role of Anthracyclines in the Treatment of Early Breast Cancer
Luca Gianni et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial
Judith Hugh et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Maggie C. U. Cheang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial
Paul Ellis et al.
LANCET (2009)
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00
G. Fountzilas et al.
ANNALS OF ONCOLOGY (2008)
Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing
Isabelle Vanden Bempt et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
HER2 and response to paclitaxel in node-positive breast cancer
Daniel F. Hayes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer
Walter Schippinger et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2007)
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system
Clifford A. Hudis et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Brain metastases: The HER2 paradigm
Nancy U. Lin et al.
CLINICAL CANCER RESEARCH (2007)
Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy
Raihanatou Diallo-Danebrock et al.
CLINICAL CANCER RESEARCH (2007)
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients:: The FNCLCC PACS 01 trial
Henri Roche et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
Lisa M. McShane et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)
BC Pestalozzi et al.
ANNALS OF ONCOLOGY (2006)
Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy
Ioannis Kostopoulos et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Current status of dose-dense chemotherapy for breast cancer
AD Seidman
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group
G Fountzilas et al.
ANNALS OF ONCOLOGY (2005)
Dose density in adjuvant chemotherapy for breast cancer
ML Citron
CANCER INVESTIGATION (2004)
Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival
KD Miller et al.
ANNALS OF ONCOLOGY (2003)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: A Hellenic cooperative oncology group phase II study
G Fountzilas et al.
CANCER INVESTIGATION (2000)
Share Paper
